Doximity's Wild Ride: Stock Drop and AI Surge
Update: 2025-10-10
Description
Doximity shares plunged almost 7% after JP Morgan downgraded the stock, citing high valuation and digital ad uncertainty, particularly in pharma. Is this a buying opportunity or a warning sign? Despite the volatility and premium price compared to its peers, Doximity's stock is still up 26% year-to-date, fueled by AI optimism. Find out if this dip changes the long-term outlook for the physician networking giant.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
